Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multiple studies have examined the effect of endogenous GLP-1 secretions by using a competitive antagonist of GLP-1 - Exendin-9,39 - infused at rates of 300pmol/kg/min. However, the presence of an effect does not necessarily imply that this effect is due to the blockade of the endogenous GLP-1 actions at the receptor. It is possible that the supraphysiologic concentrations of Exendin may have effects of its own. To examine the effect of Exendin on glucose metabolism the investigators propose a dose-response study to determine whether the compound has effects in a dose-dependent fashion.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Saline | Placebo Comparator |
| |
| GLP-1-(9,36)-amide | Active Comparator |
| |
| Exendin-9,39 @30pmol/kg/min | Active Comparator |
| |
| Exendin-9,39 @300pmol/kg/min | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| saline infusion | Drug | saline infused at 30ml/hour |
| |
| GLP-1-9,36 infusion |
| Measure | Description | Time Frame |
|---|---|---|
| Insulin Secretion | over 360 minutes of study |
| Measure | Description | Time Frame |
|---|---|---|
| glucagon secretion | over 360 minutes of study |
Not provided
Healthy Not on any medication other than thyroid hormone replacement or OCP No history of diabetes No prior upper GI surgery
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Adrian Vella, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 23545708 | Derived | Sathananthan M, Farrugia LP, Miles JM, Piccinini F, Dalla Man C, Zinsmeister AR, Cobelli C, Rizza RA, Vella A. Direct effects of exendin-(9,39) and GLP-1-(9,36)amide on insulin action, beta-cell function, and glucose metabolism in nondiabetic subjects. Diabetes. 2013 Aug;62(8):2752-6. doi: 10.2337/db13-0140. Epub 2013 Apr 1. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
infused @ 1.2pmol/kg/min |
|
| Exendin-9,39 at low dose | Drug | infused at 30pmol/kg/min |
|
| Exendin-9,39 at high dose | Drug | infused @ 300pmol/kg/min |
|